- Home
- BTAI vs IPWR Comparison
BTAI vs IPWR Comparison
Compare BTAI & IPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- IPWR
- Stock Information
- Founded
- BTAI 2017
- IPWR 2007
- Country
- BTAI United States
- IPWR United States
- Employees
- BTAI N/A
- IPWR N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- IPWR Industrial Machinery/Components
- Sector
- BTAI Health Care
- IPWR Industrials
- Exchange
- BTAI Nasdaq
- IPWR Nasdaq
- Market Cap
- BTAI 48.3M
- IPWR 52.8M
- IPO Year
- BTAI 2018
- IPWR 2013
- Fundamental
- Price
- BTAI $2.07
- IPWR $5.28
- Analyst Decision
- BTAI Buy
- IPWR Hold
- Analyst Count
- BTAI 5
- IPWR 1
- Target Price
- BTAI $32.80
- IPWR N/A
- AVG Volume (30 Days)
- BTAI 1.0M
- IPWR 57.7K
- Earning Date
- BTAI 11-13-2025
- IPWR 11-13-2025
- Dividend Yield
- BTAI N/A
- IPWR N/A
- EPS Growth
- BTAI N/A
- IPWR N/A
- EPS
- BTAI N/A
- IPWR N/A
- Revenue
- BTAI $868,000.00
- IPWR $19,240.00
- Revenue This Year
- BTAI N/A
- IPWR N/A
- Revenue Next Year
- BTAI $614.78
- IPWR $9,900.00
- P/E Ratio
- BTAI N/A
- IPWR N/A
- Revenue Growth
- BTAI N/A
- IPWR N/A
- 52 Week Low
- BTAI $1.17
- IPWR $3.77
- 52 Week High
- BTAI $13.28
- IPWR $8.62
- Technical
- Relative Strength Index (RSI)
- BTAI 34.40
- IPWR 47.84
- Support Level
- BTAI $2.14
- IPWR $5.43
- Resistance Level
- BTAI $2.46
- IPWR $5.81
- Average True Range (ATR)
- BTAI 0.17
- IPWR 0.37
- MACD
- BTAI 0.00
- IPWR 0.01
- Stochastic Oscillator
- BTAI 2.64
- IPWR 49.62
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About IPWR Ideal Power Inc.
Ideal Power Inc is pioneering the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.